公开(公告)号：US20230174522A1

公开(公告)日：2023-06-08

申请号：US17946101

申请日：2022-09-16

Applicant: Pfizer Inc. ,  CTXT PTY LTD

Inventor： Ylva Elisabet Bergman Bozikis ,  Oleg Brodsky ,  Michelle Ang Camerino ,  Samantha Elizabeth Greasley ,  Robert Louis Hoffman ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Paul Francis Richardson ,  Paul Anthony Stupple ,  Scott Channing Sutton

IPC: C07D413/06 ,  A61P35/04

CPC classification number: C07D413/06 ,  A61P35/04 ,  A61K45/06

Abstract: The present invention relates to compounds of formula (I)




or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.

公开(公告)号：US20210261530A1

公开(公告)日：2021-08-26

申请号：US17235836

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20200247784A1

公开(公告)日：2020-08-06

申请号：US16774786

申请日：2020-01-28

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  C07D413/12 ,  A61P35/00

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20170298048A1

公开(公告)日：2017-10-19

申请号：US15635648

申请日：2017-06-28

Applicant: Pfizer Inc.

Inventor： Michael Raymond Collins ,  Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Daniel Tyler Richter ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D405/14 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14

CPC classification number: C07D405/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US09040515B2

公开(公告)日：2015-05-26

申请号：US14132567

申请日：2013-12-18

Applicant: Pfizer Inc.

Inventor： Martin Paul Edwards ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Indrawan James McAlpine ,  Sacha Ninkovic ,  Eugene Yuanjin Rui ,  Scott Channing Sutton ,  John Howard Tatlock ,  Martin James Wythes ,  Luke Raymond Zehnder

IPC: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及通式（I）的化合物，其中R1，R2，U，V，L，M，R5，m，X，Y和Z如本文所定义，及其药学上可接受的盐， 这些化合物和盐，以及使用这些化合物，盐和组合物用于治疗异常细胞生长（包括癌症）的方法。

公开(公告)号：US11718603B2

公开(公告)日：2023-08-08

申请号：US17235836

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

CPC classification number: C07D403/12 ,  A61P35/00 ,  C07D413/12 ,  C07B2200/07

Abstract: This invention relates to compounds of Formula (I)




and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20210269425A1

公开(公告)日：2021-09-02

申请号：US17235846

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US10246433B2

公开(公告)日：2019-04-02

申请号：US15585880

申请日：2017-05-03

Applicant: Pfizer Inc.

Inventor： Martin Paul Edwards ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Indrawan James McAlpine ,  Sacha Ninkovic ,  Eugene Yuanjin Rui ,  Scott Channing Sutton ,  John Howard Tatlock ,  Martin James Wythes ,  Luke Raymond Zehnder

IPC: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D407/14 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20190040047A1

公开(公告)日：2019-02-07

申请号：US16156304

申请日：2018-10-10

Applicant: Pfizer Inc.

Inventor： Michael Raymond Collins ,  Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Daniel Tyler Richter ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D405/14 ,  C07B59/00 ,  C07D409/14 ,  C07D401/06 ,  C07D401/14 ,  C07D413/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20240140947A1

公开(公告)日：2024-05-02

申请号：US18488191

申请日：2023-10-17

Applicant: Pfizer Inc.

Inventor： Fengjuan Cao ,  Kevin Daniel Freeman-Cook ,  Rhys Marsden Jones ,  Scott Channing Sutton

IPC: C07D471/04 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61K45/06 ,  A61P35/00

Abstract: The invention relates to 4-((6-(2,2-Difluoroethyl)-8-(2-hydroxy-2-methylcyclopentyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)piperidine-1-sulfonamide or pharmaceutically acceptable salts thereof, to compositions containing them, to processes for their preparation, to intermediates used in such processes, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer. The disclosure also relates to its crystalline form 1, to pharmaceutical compositions comprising form 1, and to the use of form 1 for the treatment of cancers.